BFM
LCTX icon

Boothbay Fund Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Boothbay Fund Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.8K Hold
10,000
– – ﹤0.01% 1979
2025
Q4 		$16.7K Buy
+10,000
New +$17.3K ﹤0.01% 1890
2023
Q2 		– Sell
-74,560
Closed -$112K – 2066
2023
Q1 		$112K Buy
74,560
+466
+0.6% +$650 ﹤0.01% 1898
2022
Q4 		$86.7K Buy
+74,094
New +$93.4K ﹤0.01% 1826
2022
Q3 		– Sell
-27,777
Closed -$44K – 2431
2022
Q2 		$44K Buy
+27,777
New +$36.6K ﹤0.01% 2085
2022
Q1 		– Sell
-14,258
Closed -$35K – 2414
2021
Q4 		$35K Buy
+14,258
New +$33.4K ﹤0.01% 1791

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boothbay Fund Management's LCTX Position: Q1 2026 in Review

Boothbay Fund Management held its Lineage Cell Therapeutics (LCTX) position steady in Q1 2026 at 10,000 shares worth $15.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1979.

Boothbay Fund Management first reported a position in LCTX in Q4 2021 and has held it in 6 quarters since. The position peaked at $112K in Q1 2023. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Boothbay Fund Management held 10,000 shares of Lineage Cell Therapeutics worth $15.8K as of Q1 2026.
  • Boothbay Fund Management left its Lineage Cell Therapeutics share count unchanged in Q1 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1979 holding.
  • Boothbay Fund Management first reported a position in Lineage Cell Therapeutics in Q4 2021 and has held it in 6 quarters since.
  • Boothbay Fund Management's Lineage Cell Therapeutics position peaked at $112K in Q1 2023.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.